New glioblastoma trial opens in Wellington

The Gillies McIndoe Research Institute (GMRI) in collaboration with Health NZ / Te Whatu Ora has recently announced the opening of their Phase 2 glioblastoma (GBM) clinical trial.

The trial, named “Targeting Renin-Angiotensin System In Glioblastoma (TRAS-GB)”, uses a suite of repurposed drugs which targets the renin angiotensin system (RAS) and associated pathways. It builds on the progress made in their earlier Phase 1 trial which was conducted in patients with recurrent GBM. The earlier trial showed that the repurposed drugs were safe and well-tolerated by the patients.

The Phase 2 trial is open to patients with newly diagnosed with glioblastoma which means that the patients will receive the experimental protocol earlier in their treatment pathway alongside the standard treatments of surgery, radiotherapy and chemotherapy.

GMRI have produced the below video introducing the new clinical trial.

If you are interested in participating in this trial, please speak to your oncologist.

For more information about the trial, please contact the Gillies McIndoe Research Institute Email: info@gmri.org.nz, Phone: +64 4 2820366, Address: Level 3, 7 Hospital Road, Newtown, Wellington 6021